BackSummit Therapeutics Overview
Summit Therapeutics Inc

Summit Therapeutics Target Price

Analysts' average 12-month price target for Summit Therapeutics is $27.

Get informed when a big investor buys or sells

+ Follow

Share Price

$17.12

Average Target Price

$26.8256.6% upside

6 analysts in the last 4 months

High: $38 | Low: $11.9

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-09-09Summit Redstone PartnersFaisal Khurshid$2546% upsideOpen
2026-09-08UBSDavid Dai$3392.8% upsideOpen
2026-08-25Summit Redstone PartnersJeffrey Walch$11.930.5% downsideOpen
2026-07-24Jefferies$1512.4% downsideOpen
2026-07-24Stifel NicolausDara Azar$38122% upsideOpen
2026-07-24GuggenheimBrad Canino$38122% upsideOpen
2026-05-04H.C. Wainwright$2334.3% upsideOpen
2026-05-01Piper Sandler$166.5% downsideOpen
2026-02-24H.C. Wainwright$3075.2% upsideOpen
2026-01-14Piper Sandler$40133.6% upsideOpen
2025-12-17Summit Redstone PartnersEtzer Darout$185.1% upsideOpen
2025-10-21H.C. Wainwright$40133.6% upsideOpen
2025-10-21Barclays$166.5% downsideOpen
2025-09-16Summit Redstone Partners$1324.1% downsideOpen
2025-08-19Summit Redstone PartnersKelsey Goodwin$2122.7% upsideOpen
2025-04-28H.C. Wainwright$44157% upsideOpen
2025-04-25Wells Fargo$3075.2% upsideOpen
2025-04-25JefferiesKelly Shi$44157% upsideOpen
2025-03-26Summit Redstone PartnersYigal Nochomovitz$35104.4% upsideOpen
2025-02-28Summit Redstone Partners$42145.3% upsideOpen
2024-11-04JMP SecuritiesReni Benjamin$3286.9% upsideOpen
2024-09-27Summit Redstone PartnersYigal Nochomovitz$2334.3% upsideOpen
2024-09-25Stifel NicolausBrad Canino$40133.6% upsideOpen
2024-09-16H.C. WainwrightMitchell Kapoor$45162.9% upsideOpen
2024-06-03Stifel NicolausBrad Canino$1418.2% downsideOpen
2024-03-25Stifel NicolausBrad Canino$853.3% downsideOpen

Summit Therapeutics (SMMT) FAQ

Summit Therapeutics posts a target price of $27. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

A target price of $27 for SMMT means covering analysts, on average, see the stock 56.6% upside of $17.12 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.

Context for SMMT's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Summit Therapeutics's other metric pages and overview cover the third.